Boston Scientific Corporation ($BSX) Stock Forecast: Down 5.3% Today

What is Boston Scientific Corporation?

Boston Scientific Corporation (BSX) is a leading medical technology company that specializes in manufacturing medical devices across various interventional medical specialties such as cardiology, urology, endoscopy, and neuromodulation.

Why is Boston Scientific Corporation going down?

BSX stock is down 5.3% on Apr 24, 2026 19:15

• Boston Scientific Corp. experienced a notable downward trend in its stock price today, despite receiving positive updates and showing resilience in the market.
• Concerns arose as Johnson & Johnson initiated a direct comparison clinical trial between Varipulse and Boston Scientific's Farapulse for treating atrial fibrillation, potentially impacting market competition and share.
• While the company saw a strong start and reported impressive quarterly net sales, the decline in stock value could be linked to investors taking profits following recent growth.
• The overall market's negative performance today likely also weighed on BSX shares, despite the company's recent market outperformance.

BSX Price Chart

BSX Technical Analysis

BSX News

5 Early Q1 Earnings Winners Beating Expectations

This article highlights five companies that have beaten their Q1 earnings expectations: GE Vernova, Intuitive Surgical, Masco Corp., Boston Scientific, and Rogers Communications. It discusses the financial performance and future outlook for each company, noting strong growth, backlog increases, strategic capital spending cuts, and signs of potential stock reversals supported by technical indicators. The article suggests these companies have momentum to continue into the second half of 2026 despite some current challenges.

https://www.benzinga.com/markets/large-cap/26/04/52039223/5-early-q1-earnings-winners-beating-expectations

Johnson & Johnson launches head-to-head PFA trial pitting Varipulse against Boston Scientific's Farapulse

Johnson & Johnson has initiated a head-to-head clinical trial, PERSIGMA RCT, to compare its Varipulse Pro PFA platform against Boston Scientific's Farapulse system for treating persistent atrial fibrillation. The study aims to provide comparative evidence for these two leading pulsed field ablation (PFA) technologies, enrolling up to 466 patients across 50 sites. J&J emphasizes its Varipulse Pro's new pulse sequence designed for improved efficiency and safety.

https://www.massdevice.com/johnson-johnson-boston-scientific-pfa-trial/

Edwards Lifesciences raises FY26 guidance following strong Q1

Edwards Lifesciences has increased its full-year 2026 growth outlook to 9-11% from 8-10%, driven by better-than-expected Q1 performance with revenues of $1.65bn. The primary contributor was its transcatheter aortic valve replacement (TAVR) business, which saw 14.4% year-over-year growth, contributing $1.2bn to sales. The company now projects full-year sales between $6.5bn and $6.9bn, with earnings per share expected to be $2.95 to $3.05.

https://www.medicaldevice-network.com/news/edwards-lifesciences-raises-fy26-guidance-following-strong-q1/

Boston Scientific Corp. Opens with 4.84% Gain, Outperforming S&P 500's 1.05% Increase

Boston Scientific Corp. had a strong opening, gaining 4.84% and outperforming the S&P 500's 1.05% increase. The company reported robust quarterly net sales of USD 5,061 million with 12.73% annual growth and solid operating cash flow of USD 4,285 million, indicating strong fundamentals despite some bearish technical indicators. Its one-day performance was 8.99%, though it saw a 6.64% decline over the past month.

https://www.marketsmojo.com/news/stocks-in-action/boston-scientific-corp-opens-with-484-gain-outperforming-sp-500s-105-increase-3959687

Boston Scientific Corp. stock outperforms competitors on strong trading day

Boston Scientific Corp. (BSX) stock rose 1.26% to $65.69 on Thursday, marking its second consecutive day of gains. This performance occurred during a generally negative trading session where the S&P 500 Index and Dow Jones Industrial Average both experienced declines. The article highlights BSX's outperformance relative to the broader market.

https://www.marketwatch.com/data-news/boston-scientific-corp-stock-outperforms-competitors-on-strong-trading-day-b549020c-79a5265b2c3f

Trending Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Down 8.4% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 5.2% Today

Centene Corporation ($CNC) Stock Forecast: Up 12.8% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Down 5.2% Today

Spotify Technology S.A. ($SPOT) Stock Forecast: Down 15.5% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.1% Today

Coca-Cola Company (The) ($KO) Stock Forecast: Up 5.2% Today

Newell Brands Inc. ($NWL) Stock Forecast: Down 5.0% Today

UnitedHealth Group Incorporated (DE) ($UNH) Stock Forecast: Up 5.1% Today

Boston Scientific Corporation Price History

21.03.2026 - BSX Stock was down 5.1%

• Boston Scientific Corp. (BSX) saw a bearish market movement today.
• A decision to lower the price target for BSX, based on electrophysiology hospital-purchasing data and mixed reactions to recent trial results, may have influenced the negative market sentiment.
• Concerns about a slightly higher ischemic stroke rate in the trial results could have impacted investor confidence, despite some analysts maintaining positive outlooks on the company.
• Market reaction to uncertainties about BSX's electrophysiology segment performance and the trial results' potential impact on revenue projections likely led to the observed bearish trend today.

24.03.2026 - BSX Stock was down 5.3%

• BSX stock had a bearish movement today, possibly influenced by the comparison trial announcement between Johnson & Johnson's Varipulse Pro PFA platform and Boston Scientific's Farapulse system. Concerns about competition and market share might have impacted investor sentiment.
• Despite the bearish movement, BSX has recently shown strong performance compared to peers and the broader market, indicating resilience and growth potential. This decline could be a temporary setback rather than a long-term trend.
• Analysts maintain a Buy rating on Boston Scientific, emphasizing significant upside potential, suggesting the company's solid fundamentals. Investors may view the current dip as a buying opportunity in anticipation of future growth.

24.03.2026 - BSX Stock was down 5.3%

• Boston Scientific Corp. experienced a notable downward trend in its stock price today, despite receiving positive updates and showing resilience in the market.
• Concerns arose as Johnson & Johnson initiated a direct comparison clinical trial between Varipulse and Boston Scientific's Farapulse for treating atrial fibrillation, potentially impacting market competition and share.
• While the company saw a strong start and reported impressive quarterly net sales, the decline in stock value could be linked to investors taking profits following recent growth.
• The overall market's negative performance today likely also weighed on BSX shares, despite the company's recent market outperformance.

04.01.2026 - BSX Stock was down 13.8%

• Boston Scientific's stock (BSX) saw a significant 17% decline post its Q4 2025 earnings and revenue report.
• Despite surpassing expectations for the quarter, the stock plummeted due to lower-than-anticipated guidance for Q1 2026, raising concerns about the company's short-term outlook.
• The announcement of a $14.5 billion acquisition of Penumbra (PEN) potentially added to investor unease and the subsequent drop in BSX's stock value.
• The market's response indicates a strong emphasis on future guidance and growth prospects, leading to the sell-off of BSX shares despite positive current performance indicators.

04.01.2026 - BSX Stock was down 17.7%

• Reported an increase in profit and sales spurred by strong performance in cardiovascular and MedSurg units, but issued soft guidance for the future period, leading to a decline in share price.
• Despite exceeding earnings expectations, the stock fell significantly due to a disappointing outlook for the current quarter. Cautious 2026 revenue forecast and profit projections, slightly below expectations, contributed to the downtrend.
• Market responded unfavorably to the company's forecast of slower organic revenue growth in 2026, despite exceeding analyst estimates in the fourth quarter. This conservative outlook, alongside the integration of a major acquisition, triggered investor concerns about future growth prospects.

30.02.2026 - BSX Stock was down 5.1%

• Boston Scientific (BSX) experienced a strong bearish movement today.
• The bearish trend could be attributed to the market's reaction to the upcoming conference call discussing the company's first-quarter 2026 results. Investors might be cautious or uncertain about the financial performance and business highlights to be revealed during the call.
• Additionally, the news about the FDA 510(k) clearance for Boston Scientific's Asurys Fluid Management System targeting kidney stone procedure risks might not have been impactful enough to offset the overall negative sentiment surrounding the stock.
• The reaffirmation of a "Strong Buy" rating for First Watch Restaurant Group by Raymond James, despite recent stock decline, could have also diverted investor attention away from Boston Scientific, contributing to the bearish movement.

04.01.2026 - BSX Stock was down 15.4%

• Boston Scientific reported strong Q4 2025 earnings, beating expectations in both adjusted EPS and revenue. However, the stock plummeted due to a disappointing 2026 revenue forecast, which fell short of analyst consensus.
• The company's cautious outlook for 2026, including a projected deceleration in organic revenue growth and integration concerns related to the Penumbra acquisition, contributed to investor concerns and the subsequent bearish movement in the stock.
• Despite the positive Q4 results, the market reacted negatively to the revenue shortfall, highlighting the importance of forward-looking guidance and market sentiment in determining stock performance.
• Boston Scientific's stock underperformance in premarket trading, compared to the broader market trend, further emphasizes the impact of company-specific factors on investor confidence and stock valuation.

04.01.2026 - BSX Stock was down 15.6%

• Despite Boston Scientific beating Q4 2025 earnings and revenue estimates, the stock experienced a significant 17% drop due to weaker-than-expected guidance for Q1 2026. This disappointing outlook for the immediate future led to a bearish market movement.
• The slowdown in the growth of the electrophysiology business, particularly in the U.S. market, raised concerns among analysts and investors, contributing to the stock price decline.
• The acquisition of Penumbra for $14.5 billion could have also impacted investor sentiment, as the market may be uncertain about the potential synergies and outcomes of this significant move.
• The cautious outlook provided by Boston Scientific despite reporting increased profit and sales suggests that investors are focusing more on the company's future prospects and guidance, which in this case, did not meet expectations, leading to the bearish movement in the stock.

22.03.2026 - BSX Stock was up 5.7%

• Boston Scientific is a leading medical technology company focused on developing innovative solutions to transform patient lives.
• The stock of Boston Scientific (BSX) experienced a strong bullish movement today.
• The positive market reaction can be attributed to the company's robust first-quarter 2026 results, including significant revenue growth and exceeding earnings expectations.
• Key factors contributing to the bullish sentiment could be the successful clinical trial outcomes, regulatory approvals, and strategic acquisitions announced by Boston Scientific.
• Investors likely responded favorably to the company's updated full-year guidance, reflecting confidence in its growth trajectory and market positioning.

22.03.2026 - BSX Stock was up 7.2%

• Boston Scientific is a leading medical technology company focusing on innovative solutions to enhance patient care. The company has a history of positive clinical trial outcomes and meeting regulatory milestones.
• Net sales for Boston Scientific saw an 11.6% increase in the first quarter of 2026. The company surpassed its earnings per share (EPS) expectations, reflecting strong financial performance.
• Positive results from clinical trials of key medical devices like the WATCHMAN FLX™ and EKOS™ systems have boosted investor confidence in the company's growth trajectory.
• The market reacted favorably to Boston Scientific's optimistic guidance for the full year and second quarter of 2026, signaling expected sales growth and a positive outlook.
• Boston Scientific's robust financial performance and promising future outlook likely drove investor confidence and contributed to the bullish movement in its stock price.

22.03.2026 - BSX Stock was up 5.8%

• Boston Scientific reported impressive first-quarter 2026 results, surpassing expectations with significant revenue growth and positive clinical trial outcomes for key medical devices.
• Despite the positive financial performance, the stock initially experienced a decline, potentially due to broader sector pressure or market participants expecting a normalization in growth after the strong results.
• The appointment of Aamir Paul as the new CEO of Regal Rexnord, a move from Schneider Electric, might have also influenced market sentiment positively, reflecting leadership changes in related industries.
• Overall, Boston Scientific's robust performance and strategic advancements in its product portfolio and regulatory approvals likely contributed to the bullish movement in its stock price today.

22.03.2026 - BSX Stock was up 8.5%

• Despite adjustments to its 2026 guidance related to challenges in its electrophysiology, Watchman, and urology segments, Boston Scientific's stock witnessed a significant bullish movement.
• Market response was likely influenced by the company's strong performance in the first quarter of 2026, marked by substantial revenue growth and positive future outlook.
• Investors may interpret the revised guidance as a proactive measure to tackle present difficulties and position the company for growth, leading to optimistic sentiment towards the stock.
• The market appears to be focusing on Boston Scientific's strategic initiatives and long-term prospects, driving up the stock's value despite the revised projections.